Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROS1 | P08922 | 1/20 | 0.72 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.72 |
| ▸ | MAPK8 | P45983 | 12/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 12/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 11/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019570 | 0.85 | ROS1 (0.69) | ROS1RPS6KB1MAPK8MAPK10MAPK9 | |
| SCHEMBL4024880 | 0.84 | ROS1 (1.00) | ROS1RPS6KB1MAPK8MAPK10MAPK9 | |
| SCHEMBL4019238 | 0.82 | TRPV1 (0.69) | TRPV1 | |
| SCHEMBL4022503 | 0.81 | ROS1 (0.80) | ROS1RPS6KB1MAPK8MAPK10MAPK9 | |
| SCHEMBL4022175 | 0.79 | ROS1 (0.73) | ROS1RPS6KB1MAPK8MAPK10MAPK9 | |
| SCHEMBL4030518 | 0.77 | ROS1 (0.64) | ROS1RPS6KB1TRPV1GLSALDH1A1 | |
| SCHEMBL4026467 | 0.77 | ROS1 (0.73) | ROS1RPS6KB1TRPV1KMT2A | |
| SCHEMBL5391279 | 0.77 | ROS1 (0.81) | ROS1RPS6KB1MAPK8MAPK10MAPK9 | |
| SCHEMBL4024838 | 0.74 | ROS1 (0.69) | ROS1RPS6KB1MAPK8MAPK10MAPK9 | |
| SCHEMBL4022606 | 0.74 | TRPV1 (0.70) | ROS1RPS6KB1MAPK8MAPK10MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478363-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2009-01-14 | — | — | EP | claimed |
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2008-09-04 | — | — | US | claimed |
| CN-1863777-A | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2006-11-15 | — | — | CN | claimed |
| US-7074805-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-07-11 | — | — | US | claimed |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2005-05-26 | — | — | US | claimed |
| EP-1478363-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBVIE INC. | 2004-10-21 | — | — | US | claimed |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-08-12 | — | — | US | claimed |
| WO-2003070247-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | claimed |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2003-08-21 | — | — | US | claimed |
| US-8247413-B2 | e.g. N-[2-(3-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea; opioid receptor inhibitor; analgesic, antiinflammatory agent; inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity | ABBOTT LABORATORIES (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1478363-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2008-09-04 | — | — | US | disclosed |
| US-7335678-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBOTT LABORATORIES (US) | 2008-02-26 | — | — | US | disclosed |
| CN-1863777-A | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2006-11-15 | — | — | CN | disclosed |
| EP-1478363-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBVIE INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2003070247-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | TRPV1, TMEM109, VIPR1 | ROS1 1146/4885RPS6KB1 671/4885MAPK8 1654/4885 |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | ROS1 1132/4885RPS6KB1 729/4885MAPK8 1702/4885 |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | ROS1 1209/4885RPS6KB1 718/4885MAPK8 1732/4885 |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | TRPV1, TMEM109, GPR55 | ROS1 1265/4885RPS6KB1 1122/4885MAPK8 1645/4885 |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | ROS1 1146/4885RPS6KB1 671/4885MAPK8 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.